^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    REC-617

    i
    Other names: REC-617, GTAEXS617, GTAEXS-617, EXS 617, EXS617, EXS-617, REC617, REC 617
    Associations

    News

    Trials
    Company:
    Recursion Pharma
    Drug class:
    CDK7 inhibitor
    Related drugs:
    Associations

    News

    Trials
    2ms
    ELUCIDATE: Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=230, Recruiting, Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. | N=165 --> 230
    Enrollment change
    |
    HER-2 (Human epidermal growth factor receptor 2) • CDK4 (Cyclin-dependent kinase 4) • CDK6 (Cyclin-dependent kinase 6)
    |
    HR positive
    |
    Avastin (bevacizumab) • paclitaxel • capecitabine • fulvestrant • REC-617
    over2years
    ELUCIDATE: Study to Assess GTAEXS617 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=170, Recruiting, Exscientia AI Limited
    New P1/2 trial • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • CDK6 (Cyclin-dependent kinase 6) • CD4 (CD4 Molecule)
    |
    HER-2 negative
    |
    REC-617